Phase 3 study of ibrutinib in combination with venetoclax in subjects with mantle cell lymphoma (MCL)
Clinical Trial Information
Trial Contact: Walton, Sherri; Manchola-Orozco, Carolina
This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.
Subjects with mantle cell lymphoma confirmed and documented.
Adequate hematologic function
Adequate hepatic and renal function